Treatment of chemotherapy-refractory metastatic urothelial tumors.
Patients with unresectable bladder carcinoma unresponsive to standard chemotherapy have a short survival, but recent clinical trials of salvage treatment have produced some good results. Changes in the dosage of M-VAC; 5-fluorouracil, alpha-interferon, and cisplatin; and gallium nitrate show promise.
Logothetis
C
C
Department of Medical Oncology, U.T. M. D. Anderson Cancer Center, Houston.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary* / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005708:Gallium / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D014747:Vinblastine; D004317:Doxorubicin; D005708:Gallium; D002945:Cisplatin; C027235:gallium nitrate; D008727:Methotrexate